Common questions about Intrinsa (Testosterone) (FAQ)
Q: Is it normal to feel a tingling sensation where the Intrinsa patch is applied?
A: Official regulatory documents categorize application site reactions, such as redness (erythema) and itching, as a Very Common side effect. While a tingling sensation is not specifically named, it falls within the general category of reactions that may occur where the patch is placed on the skin.
Q: Can the Intrinsa patch fall off while swimming or showering?
A: The patch is generally engineered to adhere during normal activities like bathing or showering. However, official information on the patch’s use does not specifically address swimming. If the patch detaches prematurely, regulatory documents specify that the original twice-weekly treatment schedule should be maintained.
Q: Can Intrinsa cause changes in mood or emotional stability?
A: Adverse event listings in official product documentation do not list mood swings or emotional instability as common side effects. However, side effects categorized under Nervous System Disorders, such as headaches and migraines, are documented.
Q: Why do doctors check liver function while someone is on Intrinsa?
A: Official regulatory information notes that the safety and effectiveness of Intrinsa have not been established in patients with hepatic impairment (poor liver function). Therefore, careful medical monitoring and assessment for pre-existing liver conditions are described as necessary during use.
Q: Can Intrinsa be cut in half to change the dosage?
A: The Intrinsa patch is a specialized matrix-type system designed to deliver a specific, standardized dose of testosterone continuously through the skin. Official regulatory documents specify the application of a single, whole patch, and do not provide instructions or authorization for cutting the patch for any purpose.
Q: If I stop using Intrinsa, what happens to my hormone levels?
A: Upon stopping treatment, regulatory information notes that the acquired virilisation effects (such as voice deepening or clitoral enlargement) may be irreversible. The specific decline in hormone levels back to baseline is not explicitly detailed in the official documents.
Q: Why is Intrinsa sometimes mentioned with discussions about Hypoactive Sexual Desire Disorder (HSDD)?
A: Intrinsa was clinically studied and approved by regulatory agencies for the treatment of Hypoactive Sexual Desire Disorder (HSDD). This indication is specific to women who had undergone surgical menopause and were receiving concomitant estrogen therapy.
Q: Will I need ongoing blood tests while using Intrinsa?
A: Official label information describes the need for specific clinical monitoring when the patient has certain co-administered medications or pre-existing cardiovascular conditions. This monitoring may include checks for blood pressure and blood clotting factors.
Q: What is considered an overdose of Intrinsa?
A: An overdose is not specifically defined in the documents, but signs of testosterone excess can manifest as virilisation (development of male characteristics), such as voice deepening or clitoral enlargement. These are signs that may require immediate review and cessation of therapy.
Q: What is the difference between Intrinsa and testosterone gels or injections?
A: Intrinsa is a transdermal patch that delivers the hormone through the skin, avoiding the extensive processing by the liver (hepatic first-pass metabolism) that occurs with oral forms of medicine. The transdermal route is engineered to provide stable hormone concentrations, which is a key differentiator from other delivery forms.
Q: How quickly can someone expect to notice changes after starting Intrinsa?
A: The official protocol mandates that a clinical evaluation of the treatment response should be formally conducted by a healthcare provider within 3 to 6 months of starting the patch. This is the official timeframe for determining efficacy, but information on the earliest expected personal observation of effects is not provided.
Q: Is it safe to use Intrinsa if I'm already taking blood thinners?
A: The use of Intrinsa with oral anticoagulants, such as warfarin (a blood thinner), may change the blood’s clotting activity. Official regulatory documents indicate that co-administration requires closer and more frequent monitoring of the blood's clotting factors as part of the close and frequent monitoring required to manage the interaction.
Q: Is weight gain or weight loss a known side effect of Intrinsa?
A: Official documents classify an increase in weight as a Common side effect (ge 1/100 to < 1/10). The adverse reaction profile does not explicitly list weight loss as a reported side effect.
Q: Does Intrinsa affect blood pressure or cholesterol levels?
A: Official regulatory documents note that special careful monitoring is required for patients with pre-existing cardiovascular conditions, including hypertension (high blood pressure). The official documentation does not explicitly detail the drug’s effects on cholesterol levels.
Q: Is Intrinsa approved for use in women before menopause?
A: The regulatory authorization for Intrinsa is strictly limited to women who have experienced surgically induced menopause and are already receiving concomitant estrogen therapy. Safety and effectiveness have not been evaluated or established for use in women before or during natural menopause.
Q: Did the FDA or similar bodies conduct a lot of studies on Intrinsa before approval?
A: Regulatory review for Intrinsa included evidence from Phase 3 Core Trials and other randomized, placebo-controlled trials that assessed its effects and safety profile. Official approval is granted only after a comprehensive review of these pivotal studies by government health authorities.
Q: Is it possible to have an allergic reaction to the Intrinsa patch adhesive?
A: The use of Intrinsa is strictly contraindicated in individuals with a known hypersensitivity to testosterone or its excipients (the inactive ingredients in the patch, including the adhesive). Separately, common side effects include application site reactions, which are non-allergic skin changes.
Q: Does Intrinsa affect fertility or the ability to get pregnant?
A: Intrinsa is strictly contraindicated for use in women who are or may become pregnant, or who are breastfeeding. The drug is authorized only for women who have undergone surgical menopause, and no specific information regarding its effects on future fertility is detailed in the official documents.
Q: Is the small amount of testosterone in Intrinsa sufficient to cause changes?
A: The patch is specifically engineered to deliver a controlled, low dose of testosterone through the skin. This transdermal delivery system is officially described as a method for achieving stable serum-T concentrations intended to correct the hormonal imbalance following the surgical removal of the ovaries.
Q: Why are people with certain cancers advised not to use Intrinsa?
A: Intrinsa is strictly contraindicated in women with a known, suspected, or past history of breast cancer or any other estrogen-dependent neoplasia. This is due to the mechanism of action, which involves influencing hormone receptors that could potentially affect the growth of these specific types of cancer cells.
Q: Does taking Intrinsa affect how birth control pills work?
A: Intrinsa is exclusively authorized for women who have experienced surgical menopause and are already receiving estrogen therapy. The official product documentation does not establish or report on the drug's effects or interactions with oral birth control pills.
_EN.png)
